Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2Phase 1 1

Status

Terminated 3Completed 2

Sponsor Class

INDUSTRY 5OTHER 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 5

Conditions

Lymphoma, Non-Hodgkin 5Recurrence 2

Interventions

Rituximab 376Cyclophosphamide 179Bendamustine Hydrochloride 109obinutuzumab 100Vincristine 94fludarabine 92ibrutinib 89Prednisone 89Doxorubicin 89venetoclax 86Lenalidomide 82Gemcitabine 65acalabrutinib 48Brentuximab Vedotin 44pembrolizumab 43zanubrutinib 41Dexamethasone 41idelalisib 37ofatumumab 32Oxaliplatin 30Chlorambucil 29polatuzumab vedotin 25blinatumomab 25tocilizumab 24Azacitidine 24tositumomab I-131 22Prednisolone 22tisagenlecleucel 21glofitamab 21Nivolumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × galiximab × Lymphoid × Clear all
NCT00384150 2015-11-26

Retreatment Study of Galiximab + Rituximab in Follicular Non-Hodgkin's Lymphoma (NHL)

Biogen

Phase 3 Terminated
16 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00363636 2015-10-02

A Study of Galiximab + Rituximab Versus Rituximab + Placebo in Follicular Non-Hodgkin's Lymphoma (NHL)

Biogen

Phase 3 Terminated
340 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Recurrence

NCT00048555 2013-09-16

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Biogen

Phase 1/2 Completed
90 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT00575068 2012-06-08

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Biogen

Phase 1/2 Completed
42 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT00651443 2011-01-07

Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma

Biogen

Phase 1 Terminated
20 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡